Phaseline

Targets › IGHE

IGHE (Immunoglobulin heavy constant epsilon): drug programs, companies and trials

2 programs from 2 companies in 8 trials: 3 Phase 4, 3 Phase 2, 2 Phase 3; Immunology, Infectious disease, Other; next expected readout May 2028.

Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. (UniProt, P01854)

Open in Phaseline: the race on IGHE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisOmalizumab
Ig epsilon chain C region inhibitor
IGHEPhase 3Chronic Spontaneous Urticaria; Food Allergy; Asthma; Chronic Sinusitis …May 2028
Taizhou Mabtech PharmaceuticalOmalizumab (CMAB007)
Ig epsilon chain C region inhibitor
IGHEPhase 3Chronic Spontaneous Urticaria–

Conditions

Chronic Spontaneous Urticaria (2) Asthma (2) Food Allergy (1) Chronic Sinusitis (1) Allergies (1) Asthma in Children (1)

Modalities

mixed (1), antibody (1)

Companies

Novartis (1) Taizhou Mabtech Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.